Login to Your Account



Daiichi, Coherus hit phase III marks for Enbrel biosimilar

By Cornelia Zou
Staff Writer

Friday, January 15, 2016

HONG KONG – Japanese pharma major Daiichi Sankyo Co. Ltd., looking to enter the biosimilar game, reported positive results from a co-developed drug that could become the country's first biosimilar etanercept.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription